Pharmacologic Costs of Tyrosine Kinase Inhibitors in...

Clinical Lung Cancer 2016 / 03 Vol. 17; Iss. 2

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials

Giuliani, Jacopo, Bonetti, Andrea
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
17
Language:
english
Journal:
Clinical Lung Cancer
DOI:
10.1016/j.cllc.2015.12.005
Date:
March, 2016
File:
PDF, 586 KB
english, 2016
Conversion to is in progress
Conversion to is failed